NBTY acquisition closes
This article was originally published in The Tan Sheet
Executive Summary
The Carlyle Group's $4 billion purchase of NBTY wraps up Oct. 1 after receiving an affirmative vote from the supplement firm's shareholders Sept. 22. Ronkonkoma, N.Y.-based NBTY is delisting from the New York Stock Exchange and shareholders are entitled to $55 in cash for each share of common stock. When the acquisition was announced in July, some analysts expected NBTY to attract higher bids during its 35-day "go-shop" period, but none materialized (1"The Tan Sheet" July 19, 2010)
You may also be interested in...
Carlyle Group's $3.8B Bid For NBTY Could Face Competition
The Carlyle Group's planned acquisition of NBTY for $3.8 billion may not be the only private equity offer to surface for the dietary supplement giant
Australia To Seek Stakeholder Input On Terms Of HTA Review
The review of the health technology assessment system will look at the use of adaptable and flexible approaches to managing future health care technologies, early and equitable access for patients, as well as the possibility of international work-sharing initiatives and comparisons of purchasing practices.
Sandoz Gains An Edge With High-Concentration US Humira Biosimilar
Sandoz has gained a potential advantage ahead of being part of a second wave of Humira biosimilar competition hitting the US, with the firm obtaining FDA approval for its Hyrimoz version of adalimumab in a citrate-free high-concentration formulation.